MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
N-Acetyl Selank Amidate Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
N-Acetyl Selank Amidate is a stabilized analog of Selank, a tuftsin-derived heptapeptide anxiolytic. Adding N-terminal acetylation and C-terminal amidation caps both ends of the molecule against peptidase cleavage, the goal being a longer-acting version of Selank's effects [2][8]. Like the parent, it is studied as a non-benzodiazepine positive allosteric modulator of GABA signaling that also raises BDNF, producing calm and cognitive support without sedation, tolerance, or withdrawal in the parent compound's Russian trials [1][8]. Real-world use is intranasal at 600-900 mcg/day in 2-3 divided doses, typically cycled 14 days on with a washout. No human trials of the amidate itself have been published, so its profile is inferred from Selank. It is not FDA, EMA, or MHRA approved and is a research-only compound outside Russia. The subcutaneous reconstitution figures on this page are an educational dosing-math reference, not the validated route.
Reconstitute: Add 2 mL bacteriostatic water → 5 mg/mL concentration.
Typical dose: 600-900 mcg/day (intranasal, divided 2-3x daily)
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 0.0500 mg (50 mcg) on a U-100 insulin syringe.
Storage: Lyophilized powder stored frozen or at −20°C; reconstituted solution refrigerated (2–8°C) and used within ~3–4 weeks; protect from light and avoid repeated freeze–thaw.
Half-life: Not established for the amidate; parent Selank is ~a few minutes in plasma, and the acetyl/amide caps are expected to extend stability (estimate only).
Route: Intranasal in real-world use (2-3x daily); the subcutaneous protocol here is an educational reconstitution reference.
Status: Not FDA/EMA/MHRA approved; research-use-only outside Russia, where only parent Selank is a prescription nasal solution.
About N-Acetyl Selank Amidate
N-Acetyl Selank Amidate is a chemically stabilized analog of Selank, a tuftsin-derived heptapeptide with anxiolytic and anti-asthenic (anti-fatigue) activity demonstrated in human clinical trials of the parent molecule [1][2]. N-terminal acetylation and C-terminal amidation are added to slow enzymatic degradation, the rationale being a longer-lasting version of Selank's GABA-modulating, BDNF-raising effects [2][8].\n\nClinically and in nootropic practice this peptide is taken intranasally, not by injection. The subcutaneous figures below are an educational reconstitution reference, modeled the same way the rest of this site standardizes dosing math so the numbers stay comparable across compounds. Real-world research dosing is 600-900 mcg/day intranasally, split into 2-3 administrations of roughly 300 mcg.\n\nEducational guide for reconstitution and daily dosing\n\nFrequency: In this educational model, inject once daily subcutaneously (real-world use is intranasal, 2-3 times daily). A common pattern is a 14-day course followed by a 1-3 week washout to limit any GABA-receptor desensitization [3]. Start at the low end and titrate upward only as tolerated.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inside wall of the vial; do not spray directly onto the lyophilized powder and avoid foaming.
Gently swirl or roll the vial until fully dissolved (do not shake vigorously, as peptides are fragile). This yields 5 mg/mL, so 50 mcg per insulin-syringe unit.
Swab the injection site, then inject the measured dose slowly and steadily into subcutaneous tissue; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; store the reconstituted vial refrigerated (2–8°C) and use within about 3–4 weeks.
Interactive N-Acetyl Selank Amidate Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 2mL water yields 5.00 mg/mL. To evaluate a 250mcg dose, pull to 5.0 units (5 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Weeks 1–2 (initiation) | 300 mcg | 6 units (0.06 mL) |
| Weeks 3–4 (standard) | 600 mcg | 12 units (0.12 mL) |
| Maintenance / upper range (as tolerated) | 900 mcg | 18 units (0.18 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (N-Acetyl Selank Amidate, 10 mg each):
- check8 weeks (~600 mcg/day): ≈ 4 vials
- check12 weeks (~600 mcg/day): ≈ 5-6 vials
- check16 weeks (~600 mcg/day): ≈ 7 vials
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 2 mL per vial for reconstitution.
- check8 weeks (4 vials): 8 mL → 1 × 10 mL bottle
- check12 weeks (6 vials): 12 mL → 2 × 10 mL bottles
- check16 weeks (7 vials): 14 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → 2 × 100-count boxes
- check12 weeks: 168 swabs → 2 × 100-count boxes
- check16 weeks: 224 swabs → 3 × 100-count boxes
Mechanism of Action (MOA)
N-Acetyl Selank Amidate is built on the Selank scaffold: the tuftsin tetrapeptide Thr-Lys-Pro-Arg extended at the C-terminus with Pro-Gly-Pro to resist serum aminopeptidases. The amidate variant adds two further terminal modifications, N-terminal acetylation (Ac-) and C-terminal amidation (-NH2). Acetylation caps the free alpha-amino group that aminopeptidases recognize, while amidation neutralizes the C-terminal carboxylate targeted by carboxypeptidases; together these block the two principal exopeptidase routes that clear linear peptides, so the molecule is expected to persist longer in plasma and tissue than native Selank [2][8].\n\nNative Selank already has a short plasma half-life of only a few minutes, with rodent intranasal bioavailability modeled near 92%. The terminal caps are intended to extend that window, but no peer-reviewed pharmacokinetic study of the amidate itself has been published, so any specific half-life figure should be treated as a vendor estimate rather than established data.\n\nMechanistically the analog is expected to reproduce Selank's pharmacology. Selank acts as a positive allosteric modulator of GABA binding rather than an orthosteric benzodiazepine-site agonist [8], and it shifts the expression of dozens of neurotransmission-related genes, including GABA-A receptor subunits, in frontal cortex and neuroblastoma models [2][4]. This indirect GABAergic potentiation produces anxiolysis without the sedation, ataxia, amnesia, tolerance, or withdrawal characteristic of benzodiazepines. In parallel, Selank raises BDNF and nerve growth factor messenger RNA in the hippocampus after a single intranasal dose, an effect that strengthens over 5-7 days of repeated dosing and underlies its nootropic, pro-memory profile [5]. It also modulates serotonergic and dopaminergic turnover and, through its tuftsin lineage, influences enkephalin-degrading enzyme activity and interferon signaling, giving a neuro-immune dimension to its sustained action.\n\nThe dominant real-world route is intranasal: the peptide crosses the nasal mucosa and reaches the central nervous system along olfactory and trigeminal pathways, largely bypassing the blood-brain barrier and the first-pass gut metabolism that would destroy an oral dose. The educational subcutaneous reconstitution figures on this page exist only to standardize dosing math across the site; they are not a claim that injection is the validated route. Because plasma clearance is rapid but the downstream gene-expression and BDNF effects persist for many hours after a dose, a 2-3x daily intranasal schedule is the practical regimen for the parent compound and the basis for the amidate's 600-900 mcg/day research dosing [1][3]. Cycling, roughly 14 days on followed by a washout, is the conservative default to limit receptor desensitization.
Clinical Trial Efficacy Highlights
- starNo dedicated clinical trials of N-Acetyl Selank Amidate have been published; its expected efficacy is extrapolated from the parent peptide Selank, whose terminal acetylation and amidation are intended to extend duration of the same activity [2][8].
- starIn a randomized controlled trial of 62 patients with generalized anxiety disorder and neurasthenia, intranasal Selank produced anxiolytic efficacy comparable to the benzodiazepine medazepam on the Hamilton Anxiety Scale, but unlike medazepam it improved rather than impaired attention and working memory [1].
- starVyunova and colleagues demonstrated that Selank acts as a positive allosteric modulator of [3H]GABA binding and interacts with benzodiazepine modulation at apparently distinct but partly overlapping sites, providing a molecular basis for anxiolysis without classic benzodiazepine-site agonism [8].
- starVolkova and colleagues showed that Selank administration altered the expression of genes involved in GABAergic neurotransmission, including GABA-A receptor subunits, in rat frontal cortex, supporting an indirect, gene-level mechanism of GABA potentiation [2].
- starInozemtseva and colleagues reported that a single intranasal dose of Selank increased BDNF expression in the rat hippocampus in vivo, with effects amplified by repeated dosing, evidence for the cumulative nootropic component layered on top of acute anxiolysis [5].
- starIn a chronic ethanol model, Kolik and Konstantinopolsky found that Selank prevented ethanol-withdrawal memory and attention deficits and normalized BDNF content in the hippocampus and prefrontal cortex, suggesting utility for stress- and substance-related cognitive disturbance [6].
- starKasian and colleagues showed in an unpredictable chronic mild stress model that intranasal Selank (300 mcg/kg) reduced anxiety and enhanced the effect of diazepam, indicating it can complement benzodiazepine activity rather than simply mimic it [7].
- starAn open-label clinical optimization study by Medvedev and colleagues reported that adding Selank to phenazepam in anxiety-phobic, hypochondriac, and somatoform disorders maintained efficacy while reducing benzodiazepine-related side effects, consistent with a favorable tolerability profile carried over to the amidate [3].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningBecause no human safety studies of N-Acetyl Selank Amidate exist, its risk profile is inferred from the parent Selank, which has a favorable record across two decades of Russian clinical use; the most common parent-compound effect is transient nasal irritation or mild rhinorrhea at the site of intranasal application.
- warningRoute-specific note: this educational page models subcutaneous injection, which is not the validated route; injection adds risks not seen with the intranasal product, including injection-site pain, bruising, bleeding, and infection if sterile technique is not followed.
- warningHeadache has been reported in a minority of Selank users, usually at higher cumulative daily doses and often linked to dehydration or concurrent stimulant use; it generally resolves with dose reduction and fluids.
- warningUnlike benzodiazepines, Selank does not produce documented sedation, psychomotor slowing, amnesia, tolerance, or withdrawal/rebound anxiety on discontinuation, though this has not been formally confirmed for the amidate analog.
- warningRare reports describe transient mood blunting or emotional flatness at supraphysiologic doses; this is reversible on cessation and may relate to over-modulation of serotonergic turnover.
- warningDrug-interaction data are limited; theoretical interactions with benzodiazepines, SSRIs, and MAO inhibitors are uncharacterized, and combination use should be approached cautiously and only under qualified supervision.
- warningNo teratogenicity or reproductive-toxicity data are established; use in pregnancy and lactation is not recommended in the absence of safety data, and use in minors has not been studied.
- warningRegulatory and research status: N-Acetyl Selank Amidate is not approved by the FDA, EMA, or MHRA for any indication and is sold for laboratory research use only outside Russia; nothing here is medical advice or an endorsement of human use.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical N-Acetyl Selank Amidate dosage?expand_more
In research and nootropic practice the typical N-Acetyl Selank Amidate dosage is 600-900 mcg per day administered intranasally, divided into 2-3 doses of roughly 300 mcg each, run in 14-day cycles with a 1-3 week washout. Many users start lower (300-600 mcg/day) and titrate up as tolerated. These figures are extrapolated from parent-Selank data, since no dedicated human trials of the amidate exist. The subcutaneous numbers shown on this page are an educational reconstitution reference only.
Is N-Acetyl Selank Amidate FDA approved?expand_more
No. N-Acetyl Selank Amidate is not approved by the FDA, EMA, or MHRA for any use. Only the parent peptide Selank is registered as a prescription nasal solution in Russia (for anxiety and asthenic disorders). Outside Russia, both Selank and its amidate analog are sold strictly for laboratory research use and are not approved medicines. Nothing here is medical advice.
What is the half life of N-Acetyl Selank Amidate?expand_more
No peer-reviewed pharmacokinetic study of the amidate itself has been published, so a precise half-life is not established. Native Selank has a short plasma half-life of only a few minutes. The N-terminal acetylation and C-terminal amidation in the amidate cap both peptide termini against aminopeptidase and carboxypeptidase cleavage, which is expected to extend stability, but specific human half-life figures from vendors should be treated as estimates rather than verified data.
How do you reconstitute N-Acetyl Selank Amidate for the educational subcutaneous reference?expand_more
Draw 2.0 mL of bacteriostatic water and inject it slowly down the wall of a 10 mg vial, then swirl gently until dissolved. That gives 5 mg/mL, or 50 mcg per unit on a U-100 insulin syringe, so 300 mcg is 6 units, 600 mcg is 12 units, and 900 mcg is 18 units. Store the reconstituted vial refrigerated and use within about 3-4 weeks. Remember the real-world product is an intranasal spray, not an injection.
Can N-Acetyl Selank Amidate be stacked with other peptides?expand_more
In nootropic practice it is sometimes paired with Semax or with cognition-support peptides, and the parent Selank has been studied alongside benzodiazepines, where it enhanced diazepam's anxiolytic effect rather than duplicating it [7]. However, controlled interaction and combination data for the amidate are absent, theoretical interactions with benzodiazepines, SSRIs, and MAO inhibitors are uncharacterized, and any stacking should be approached cautiously and only under qualified supervision.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing N-Acetyl Selank Amidate, plus the universal dosing calculator.
Academic References & Study Citations
Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. View Scientific Paper →
Volkova A, Shadrina M, Kolomin T, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. View Scientific Paper →
Medvedev VE, Tereshchenko ON, Kost NV, et al. [Optimization of the treatment of anxiety disorders with selank]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40. View Scientific Paper →
Filatova E, Kasian A, Kolomin T, et al. GABA, Selank, and olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol. 2017;8:89. View Scientific Paper →
Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. View Scientific Paper →
Kolik LG, Konstantinopolsky MA. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating BDNF content in the hippocampus and prefrontal cortex in rats. Bull Exp Biol Med. 2019;167(5):641-644. View Scientific Paper →
Kasian A, Kolomin T, Andreeva L, et al. Peptide selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behav Neurol. 2017;2017:5091027. View Scientific Paper →
Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based anxiolytics: the molecular aspects of heptapeptide selank biological activity. Protein Pept Lett. 2018;25(10):914-923. View Scientific Paper →